Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11254669 Fused imidazo-piperidine JAK inhibitors

Patent 11254669 was granted and assigned to Theravance on February, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Steven D. E. Sullivan0

Gary E. L. Brandt0

Lori Jean Van Orden0

Paul R. Fatheree0

Cameron Smith0

Date of Patent

February 22, 2022

0

Patent Application Number

166796760

Date Filed

November 11, 2019

0

Patent Citations

US Patent 10392386 JAK inhibitors containing a 4-membered heterocyclic amide

US Patent 10406148 Methods of treatment using a JAK inhibitor compound

US Patent 10519153 Fused imidazo-piperidine JAK inhibitors

US Patent 10100049 JAK kinase inhibitor compounds for treatment of respiratory disease

US Patent 10183942 JAK kinase inhibitor compounds for treatment of respiratory disease

US Patent 10196393 JAK inhibitors containing a 4-membered heterocyclic amide

US Patent 10208040 Fused imidazo-piperidine JAK inhibitors

US Patent 10251874 Crystalline forms of a JAK inhibitor compound

Patent Citations Received

US Patent 11667637 Fused imidazo-piperidine JAK inhibitors

0

Patent Primary Examiner

Laura L. Stockton

0

Patent abstract

The invention provides compounds of formula (I):

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11254669 Fused imidazo-piperidine JAK inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool